REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- FRUTAROM
- GAZIT GLOBE
- HAREL
- ICL
- ISRAEL CORP
- LEUMI
- MAZOR ROBOTICS
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- POALIM
- SHUFERSAL
- SODASTREAM
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 13/03/2018 >View issuer details

2018.10.22 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

2018.10.22 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi : Déclaration des transactions sur actions propres - HTML (w)

2018.10.19 | 23:58 | Permanent Information Releases / General Company News

puce Sanofi: FDA approves asthma indication for Dupixent® (dupilumab) - HTML (w)

2018.10.19 | 23:58 | Permanent Information Releases / General Company News

puce Sanofi : La FDA approuve l'indication de Dupixent® (dupilumab) dans l'asthme - HTML (w)

2018.10.19 | 13:37 | Permanent Information Releases / General Company News

puce Sanofi receives positive CHMP opinion for dengue vaccine - HTML (w)

2018.10.19 | 13:37 | Permanent Information Releases / General Company News

puce Sanofi obtient un avis positif du CHMP pour son vaccin contre la dengue - HTML (w)

2018.10.16 | 18:00 | Share History / Voting Rights and Number of Shares

puce Information concerning the total number of voting rights and shares - HTML (w)

2018.10.16 | 18:00 | Share History / Voting Rights and Number of Shares

puce Informations relatives au nombre total de droits de vote et d'actions - HTML (w)

2018.10.16 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps - HTML (w)

2018.10.16 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : Premiers résultats positifs de deux essais de phase III consacrés au Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne - HTML (w)

2018.10.15 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

2018.10.15 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi : Déclaration des transactions sur actions propres - HTML (w)

2018.10.08 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

2018.10.08 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi : Déclaration des transactions sur actions propres - HTML (w)

2018.10.01 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2589